Tempest Therapeutics, Inc. Profile Avatar - Palmy Investing

Tempest Therapeutics, Inc.

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is cu…

Biotechnology
US, South San Francisco [HQ]
Growth Rates · Payout · Yield

Dividends Over Time

  • Records
  • Forecasts [Soon]
Growth Rates
% YoY
% 3Yr
% 5Yr
% 10Yr
Key Metrics
- -% TTM Yield
- - Average Days Gap
Series
% - - Yield
- -% Payout Ratio
Cash Amount Pay Date
Cash Amount Pay Date
End of TPST's Analysis
CIK: 1544227 CUSIP: 87978U108 ISIN: US87978U1088 LEI: - UEI: -
Secondary Listings
TPST has no secondary listings inside our databases.